Table 5.
Estimates for the latent class model, four classes with country as class membership.
| Attribute and level | Latent class | ||||||||
|
|
Class 1 | Class 2 | Class 3 | Class 4 | |||||
|
|
Estimate (SE) | Estimate (SE) | Estimate (SE) | Estimate (SE) | |||||
| Collector | |||||||||
|
|
A technological company | −0.26a (0.10) | −0.37b (0.04) | −0.36b (0.06) | −0.40b (0.08) | ||||
|
|
A research project | 0.14 (0.11) | 0.15b (0.03) | 0.21b (0.05) | 0.16a (0.07) | ||||
|
|
Your health care provider (Refc) | 0.13 (N/Ad) | 0.22 (N/A) | 0.15 (N/A) | 0.25 (N/A) | ||||
| New user | |||||||||
|
|
A technological company | −0.41a (0.16) | −0.53b (0.04) | −0.07 (0.07) | −0.59b (0.09) | ||||
|
|
A pharmaceutical company | −0.12 (0.14) | −0.08 (0.04) | −0.08 (0.07) | −0.05 (0.08) | ||||
|
|
A research project | 0.17 (0.13) | 0.29b (0.05) | 0.07 (0.07) | 0.23 (0.09) | ||||
|
|
A national authority (Ref) | 0.36 (N/A) | 0.32 (N/A) | 0.08 (N/A) | 0.41 (N/A) | ||||
| Reason | |||||||||
|
|
Develop a new product or service | 0.56b (0.16) | 0.33b (0.04) | 0.04 (0.07) | 0.43b (0.09) | ||||
|
|
Promoting, advertising, or marketing | −1.06b (0.19) | −0.98b (0.06) | −0.41b (0.09) | −0.76b (0.10) | ||||
|
|
Investigate a policy initiative | 0.10 (0.14) | 0.25b (0.04) | 0.05 (0.07) | −0.05b (0.09) | ||||
|
|
Evaluate the quality (Ref) | 0.40 (N/A) | 0.40 (N/A) | 0.32 (N/A) | 0.38 (N/A) | ||||
| Information | |||||||||
|
|
Not informed | −1.47b (0.19) | −0.66b (0.06) | −2.95b (0.12) | −1.36b (0.12) | ||||
|
|
Informed | 0.02 (0.18) | −0.04 (0.05) | −0.41b (0.07) | −0.11 (0.09) | ||||
|
|
Informed and ability to opt out | 0.82b (0.19) | 0.35b (0.05) | 1.61b (0.10) | 0.84b (0.08) | ||||
|
|
Informed and consent (Ref) | 0.65 (N/A) | 0.31 (N/A) | 1.34 (N/A) | 0.51 (N/A) | ||||
| Reviewing | |||||||||
|
|
No specific review | −0.78b (0.13) | −1.07b (0.05) | −0.58b (0.07) | −0.75b (0.09) | ||||
|
|
Review of sharing | 0.43b (0.12) | 0.50b (0.04) | 0.28b (0.06) | 0.46b (0.07) | ||||
|
|
Review of sharing and use (Ref) | 0.35 (N/A) | 0.57 (N/A) | 0.30 (N/A) | 0.29 (N/A) | ||||
| Intercept | 3.60b (0.14) | 0.31b (0.04) | 0.84b (0.06) | −2.01b (0.09) | |||||
| AICe | 29,730 (N/A) | N/A | N/A | N/A | |||||
| Log-likelihood | −14,797 (N/A) | N/A | N/A | N/A | |||||
| Average class probability (%) | 27 (N/A) | 32 (N/A) | 23 (N/A) | 18 (N/A) | |||||
| Class membership | |||||||||
|
|
Constant | 0.96b (0.17) | 0.73b (0.19) | 0.87b (0.18) | Ref | ||||
|
|
Sweden | −0.29 (0.22) | 0.09 (0.23) | −0.91b (0.25) | Ref | ||||
|
|
Norway | −1.06b (0.22) | −0.78b (0.24) | −0.50a (0.22) | Ref | ||||
|
|
Iceland | −0.76b (0.22) | 0.15 (0.23) | −0.98b (0.24) | Ref | ||||
aSignificance at 5% level.
bSignificance at 1% level.
cRef: Reference category.
dN/A: not applicable.
eAIC: Akaike information criteria.